A study published in Science Translational Medicine and highlighted by Scientific American has revealed that the blood-brain barrier may remain compromised for decades after athletes retire from contact sports, creating a persistent state of chronic inflammation that could contribute to neurological disorders. This discovery provides new scientific support for blood purification technologies like Sigyn Therapeutics' CardioDialysis system, which aims to reduce systemic inflammation that drives neuroinflammatory conditions.
Researchers at Trinity College Dublin reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE), a condition most commonly diagnosed post-mortem in former NFL players. When the blood-brain barrier becomes permeable, inflammatory molecules and pathogenic toxins from the bloodstream can enter the brain, triggering neuroinflammation and abnormal accumulation of tau protein, a hallmark of CTE.
The Scientific American article Brain's Protective Barrier Stays Leaky for Years after Playing Contact Sports coincided with the journal publication, bringing attention to how systemic inflammation in the bloodstream serves as a key driver of neuroinflammation associated with disorders including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. This growing body of evidence positions broad-spectrum blood purification as a potential adjunct therapy for these conditions.
Sigyn Therapeutics CEO Jim Joyce stated that CardioDialysis may play a meaningful role in slowing neuroinflammatory disorder progression, particularly in high-risk individuals or during early disease stages. The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain. The company is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury while maintaining cardiovascular disease as its lead clinical indication.
The Trinity College study adds to mounting evidence that connects bloodstream inflammation to neurological damage, suggesting that therapies capable of broadly clearing inflammatory molecules from circulation could address multiple neurodegenerative conditions simultaneously. This approach represents a shift from single-target drug treatments to broader interventions that address the inflammatory environment contributing to disease progression across multiple neurological disorders.
